Clinical Trial

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 23, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to evaluate the effect of a high-fat, high-calorie meal on the relative bioavailability of NAL ER following single oral doses.
Trial Details
NCT Number NCT07487740
Lead Sponsor Trevi Therapeutics
Conditions Healthy Participants
Enrollment 60 participants
Start Date 2026-02-27
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-23